

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 018733/0942	SERIAL NO. 09/382,186
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT		Hans J. HANSEN et al.	
		FILING DATE 8/23/1999		GROUP ART UNIT 1644	

U.S. PATENT DOCUMENTS E

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME JAN 10 2000	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


<i>and</i>	A1	HAWKINS, et al.; "Delivery of Radionuclides to Pretargeted Monoclonal, Antibodies Using Dihydrofolate Reductase and Methotrexate in an Affinity System,"; <i>Cancer Research</i> ; Vol. 53; May 1993; pp. 2368-2373.
<i>and</i>	A2	GOODWIN et al.; "Pre-Targeted Immunoscintigraphy of Murine Tumors with Indium-111-Bifunctional Haptens,"; <i>J. Nucl. Med.</i> ; Vol. 29; 1998; pp. 226-234.
<i>and</i>	A3	STICKNEY et al.; "Bifunctional Antibody: A Binary Radiopharmaceutical Delivery System for Imaging Colorectal Carcinoma,"; <i>Cancer Research</i> ; Vol. 51; December 15, 1991;
<i>and</i>	A4	pp. 6650-6655. GAUTHEROT et al.; "Therapy for Colon Carcinoma Xenografts with Bispecific Antibody-Targeted, Iodine-131-Labeled Bivalent Hapten,"; <i>Cancer Supplement</i> ; Vol. 80; 1997; pp. 2618-2623.
<i>and</i>	A5	BARBET et al.; "Radioimmunodetection of Medullary Thyroid Carcinoma Using Indium-111 Bivalent Hapten and Anti-CEA X Anti-DTPA-Indium,"; <i>The Journal of Nuclear Medicine</i> ; Vol. 39, No. 7; July 1998.
<i>and</i>	A6	KRANENBORG et al.; "Development and Characterization of Anti-Renal Cell Carcinoma x Antichelate Bispecific Monoclonal Antibodies for Two-Phase Targeting of Renal Cell Carcinoma,"; <i>Cancer Research Supplement</i> ; Vol. 55; December 1, 1995; pp. 5864s-5867s.
<i>Incomplete ref supplied</i>	A7	CHERRY et al.; MICROPET 1: Performance Evaluation of a Very High Resolution Pet Scanner Proceedings of the 44th Annual Meeting Scientific Papers, Vol. 38, No. 5, May 1997 Supplement.

RECEIVED

EXAMINER	DATE CONSIDERED
<i>David L. Sculender</i>	5/5/01 16N 11 2000
* EXAMINER: Initial if citation considered, whether or not citation is in conformance. Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.	

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 018733/0942	SERIAL NO. 09/382,186
INFORMATION DISCLOSURE CITATION		APPLICANT Hans J. HANSEN et al.	
<i>(Use several sheets if necessary)</i>		FILING DATE 8/23/1999	GROUP ART UNIT 1648-1649

U.S. PATENT DOCUMENTS



FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

dab	A8	<p>SCHUHMACHER et al.; "Multistep Tumor Targeting in Nude Mice Using Bispecific Antibodies and a Gallium Chelate Suitable for Immunoscintigraphy with Positron Emission Tomography,"; <i>Cancer Research</i>; Vol. 55; January 1, 1995; pp. 115-123.</p>
jul	A9	<p>SHARKEY et al.; "Development of a Streptavidin--Anti- Carcinoembryonic Antigen Antibody, Radiolabeled Biotin Pretargeting Method For Radioimmunotherapy of Colorectal Cancer. Studies in A Colon Cancer Xenograft Model,"; <i>Bioconjugate Chemical</i>; Vol. 8, No. 4; 1997.</p>

EXAMINER

David A. Scerri

DATE CONSIDERED

5/5/01

* **EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

attn: Paper A5

Sheet 1 of 2

FORM PTO 1449 (modified)
 U.S. DEPARTMENT OF COMMERCE
 PATENT AND TRADEMARK OFFICE


Date Submitted to PTO:
 June 12, 2000

ATTY DOCKET NO.
 018733/0942

SERIAL NO.
 09/382,186

APPLICANT
 Hansen et al.

FILING DATE
 August 23, 1999



GROUP
 1648 1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PATENT	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>Dan</i>	B1	5,591,828	1/7/97	Bosslet et al.		530	387.3	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
<i>Dan</i>	B2	WO 96/04313	2/15/96	WORLD	—	—	English
<i>Dan</i>	B3	0 623 675 A1	11/10/93	EPO	—	—	English
<i>Dan</i>	B4	0 419 387 A1	9/20/90	EPO	—	—	French

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>Dan</i>	B5	XP-002120437	K. Bosslet et al., "Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy", Macmillan Press Ltd., British Journal of Cancer, (1991) 63/5, 681-686
<i>Dan</i>	B6	XP-002120435	Marion H.G.C. Kranenborg et al., "Development and Characterization of Anti-Renal Cell Carcinoma x Antichelate Bispecific Monoclonal Antibodies for Two-Phase Targeting of Renal Cell Carcinoma" Cancer Research, (Dec. 1995), 55 (23 Supp.), 5864S-5867S
<i>Dan</i>	B7	XP-002120770	Corine Manetti et al., "Intracellular Uptake and Catabolism of Anti-IgM Antibodies and Bi-Specific Antibody-Targeted Hapten by B-Lymphoma Cells", International Journal of Cancer, (1995), 63(2), 250-256
<i>Dan</i>	B8	XP-002116384	Manuel Bardies et al., "Bispecific Antibody and Iodine-131-Labeled Bivalent Hapten Dosimetry in Patients with Medullary Thyroid or Small-Cell Lung Cancer", Journal of Nuclear Medicine, Vol. 37, (Nov. 1996), 1853-1859
<i>Dan</i>	B9	XP-002120771	J. Barbet et al., "Radioimmunotherapy of LS174T Colon Carcinoma in Nude Mice Using an Iodine-131-Labeled Bivalent Hapten Combined with An Anti-CEA x Anti-Indium-DTPA Bispecific Antibody", Tumor Biology, (Sept. 1997), Vol. 18, No. Supp. 2, 31
<i>Dan</i>	B10	XP-002110873	Emmanuel Gautherot, "Therapy for Colon Carcinoma Xenografts with Bispecific Antibody-Targeted, Iodine-131-Labeled Bivalent Hapten", American Cancer Society, Vol. 80, No. Supp. 12, (Dec. 1997), 2618-2623
<i>Dan</i>	B11	XP-002120436	Marion H.G.C. Kranenborg et al., "Two-Step Radio Immunotargeting of Renal-Cell Carcinoma Xenografts in Nude Mice with Anti-Renal-Cell-Carcinoma x Anti-DTPA Bispecific Monoclonal Antibodies", International Journal of Cancer, (Jan. 1998), 75 (1), 74-80

EXAMINER *Daniel C. Jaenders*

DATE CONSIDERED *5/5/01*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*all use quadruplas or
 chemical coupling or no-
 info is given*

Sheet 2 of 2

FORM PTO 1449 (modified)
 U.S. DEPARTMENT OF COMMERCE
 PATENT AND TRADEMARK OFFICE

Date Submitted to PTO:
 June 12, 2000

ATTY DOCKET NO.

018733/0942

SERIAL NO.


09/382,186

APPLICANT

Hansen et al.

FILING DATE

August 23, 1999



GROUP

1648

1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>Det</i>	B12	XP-002120769	Francoise Kraeber-Bodere et al., "Phase I/II Trial of Two-Step Radioimmunotherapy in Medullary Thyroid Cancer (MTC) Using Bispecific Anti-CEA/Anti-DTPA-In Antibody and Iodine-131-Labeled Bivalent Hapten", Journal of Nuclear Medicine, (May 1998), Vol. 39, No. 5 Supp., 246
<i>Det</i>	B13	XP-002120434	Makoto Hosono et al., "Biodistribution and Dosimetric Study in Medullary Thyroid Cancer Xenograft Using Bispecific Antibody and Iodine-125-Labeled Bivalent Hapten", Journal of Nuclear Medicine, (Sep. 1998), 39 (9), 1608-1613
<i>Det</i>	B14	XP-002120432	Emmanuel Gautherot et al., "Delivery of Therapeutic Doses of Radioiodine Using Bispecific Antibody-Targeted Bivalent Haptens", Journal of Nuclear Medicine, (Nov. 1998), 39 (11), 1937-1943
<i>Det</i>	B15	XP-002120433	Francoise Kraeber-Bodere et al., "Bispecific Antibody and Bivalent Hapten Radioimmunotherapy in CEA-Producing Medullary Thyroid Cancer Xenograft", Journal of Nuclear Medicine, (Jan. 1999), 40 (1), 198-204
<i>Det</i>	B16	XP-002120429	H. Karacay et al., "Studies on a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct for radioimmunotherapy of CEA-positive tumors", American Assoc. for Cancer Research Annual Meeting (Mar. 1999), Vol. 40, 644
<i>Det</i>	B17	XP-002120430	H. Karacay et al., "Pretargeting Studies with Humanized Anti-CEA x Murine Anti-[In-DTPA] Bispecific Antibody Construct and Tc-99M/ Re-188 Labeled Peptide", Journal of Nuclear Medicine, (May 1999), Vol. 40, No. 5 Supp., 225

EXAMINER *Daniel C. Seunarine*DATE CONSIDERED *5/5/01*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*all chemical
complex*

SHEET 1 of 1

Cetechy Patent

O I P E

S C 100

FORM PTO 1449 (modified)

ATTY DOCKET NO.
018733/0884SERIAL NO.
09/337,736 10/03/2000U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
LIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)APPLICANT
Hans J. HANSEN *et al.*FILING DATE
June 22, 1999GROUP
1643

Date Submitted to PTO: October 3, 2000

OCT 05 2000

RECEIVED

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	TECH FINGER 1600/2900 FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/OR ABSTRACT
<i>out</i>	A1	EP 0263046	4/6/88		—	—	<i>RECEIVED</i>
<i>out</i>	A2	EP 0511011A	10/28/92		—	—	OCT 4 2000
<i>out</i>	A3	WO 9808875	3/5/98		—	—	<i>GROUP NO 1700</i>

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>out</i>	A4	B.T. McGuinness <i>et al.</i>	"Phage diabody repertoires for selection of large numbers of bispecific antibody fragments," <i>Nature Biotechnology</i> , 14:1149-1154 (1996).
<i>out</i>			
<i>out</i>			
<i>out</i>			
<i>out</i>	A5	M. Alt <i>et al.</i>	"Novel tetravalent and <i>bispecific</i> IgG-like antibody molecules combining single chain diabodies with the immunoglobulin gamma-1 or CH3 region," <i>FEBS LETT</i> , 454: 90-94 (1999).
<i>out</i>			
<i>out</i>	A6	T.B. Olafsen <i>et al.</i>	"IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic Cells," <i>Immunotechnology</i> , 4(2):141-153 (1998).
<i>out</i>			
<i>out</i>	A7	S.M. Kipriyanov <i>et al.</i>	"Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics," <i>J. Mol. Biol.</i> , 293(1):41-56 (1999).

EXAMINER *David A. Saenger*

DATE CONSIDERED

5/5/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.